Fundraising FoxThe Column Group — 2015 Investments
5 investments dated 2015 · listed companies and verified rows first · show all
Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)
Board seatPeter SvennilsonDavid V. Goeddel· per SEC Form D
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesVenrockThird Rock Ventures
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.
BiotechHealthtechNew York City, US
Tom Maniatis(Founder)Nancy Thornberry(Executive Officer, Director)inKenneth Clark(Executive Officer)Charles Zuker(Founder)Richard Axel(Founder)
BoardTerry McGuire(Director)in
Board seatTim Kutzkey· per SEC Form D
Co-investorsDns CapitalIllumina VenturesLux CapitalPolaris PartnersTwo Sigma Ventures
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US
Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)
BoardDavid Goeddel(Director)inMark Goldsmith(Director)
Board seatDavid V. Goeddel· per SEC Form D
Co-investorsBain Capital Life SciencesEcoR1 CapitalForesite CapitalGeneral AtlanticSofinnova VenturesWellington Management+1 more
Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.
BiotechHealthtechSan Carlos, US
Andrew Allen(Executive Officer, Director)inVassiliki Economides(Executive Officer)Matthew Hawryluk(Executive Officer)inWayne(CEO)Rachel(VP of Operations)Shefali Agarwal(Director)
Co-investorsFrazier Life SciencesGV (Google Ventures)Sofinnova VenturesREDMILEVersant Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.